FIELD: medicine, phthisiology. SUBSTANCE: it is suggested to supplement therapy by pyrazinamide, kanamycin and/or etambutol with maxaquin and protionamide, additionally. The invention enables to decrease the percentage of patients with bacillar tubercular forms distinguished by mycobacteria resistant to the main antitubercular preparations. EFFECT: higher efficiency of therapy. 1 ex, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PULMONARY TUBERCULOSIS TREATMENT METHOD | 2002 |
|
RU2195313C1 |
| METHOD FOR DECREASING RESISTANCE OF TUBERCULAR MYCOBACTERIA TO RIFAMPICIN AND ETHAMEBUTOL IN AN EXPERIMENT | 1999 |
|
RU2185162C2 |
| METHOD FOR FORMING A CHEMOTHERAPY REGIMEN FOR PRIMARY INTRATHORACIC TUBERCULOSIS IN CHILDREN FROM TUBERCULOSIS INFECTION CENTERS | 2018 |
|
RU2704816C1 |
| METHOD FOR TREATING BACILLARY FORM OF PULMONARY TUBERCULOSIS | 2001 |
|
RU2240806C2 |
| METHOD OF TREATMENT OF PULMONARY TUBERCULOSIS | 2006 |
|
RU2340372C2 |
| ANTITUBECULOUS-CAUSED MEDICAMENTOUS POLYNEUROPATHY APPROACH | 2007 |
|
RU2353360C2 |
| COMBINED ANTITUBERCULAR PREPARATION AND METHOD FOR ITS OBTAINING | 2001 |
|
RU2182483C1 |
| COMBINED ANTITUBERCULOUS DRUG AND METHOD FOR PREPARING THEREOF | 2008 |
|
RU2431487C2 |
| METHOD FOR TREATING HUMAN TUBERCULOSIS | 2002 |
|
RU2238091C2 |
| METHOD FOR PREDICTION OF RISK OF MYCOBACTERIUM TUBERCULOSIS RESISTANCE TO FLUOROQUINOLONES IN TUBERCULOSIS PATIENTS WITH MULTIPLE RESISTANCE | 2014 |
|
RU2558992C1 |
